David A. Gremse

ORCID: 0000-0003-2277-793X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastroesophageal reflux and treatments
  • Helicobacter pylori-related gastroenterology studies
  • Eosinophilic Esophagitis
  • Esophageal and GI Pathology
  • Infant Health and Development
  • Metabolism and Genetic Disorders
  • Microscopic Colitis
  • Neuroscience of respiration and sleep
  • Inflammatory Bowel Disease
  • Gastrointestinal disorders and treatments
  • Neonatal Respiratory Health Research
  • Mitochondrial Function and Pathology
  • Gastrointestinal motility and disorders
  • Adolescent and Pediatric Healthcare
  • Child Nutrition and Feeding Issues
  • Liver Diseases and Immunity
  • Childhood Cancer Survivors' Quality of Life
  • Gallbladder and Bile Duct Disorders
  • Pharmacological Effects and Toxicity Studies
  • Liver Disease and Transplantation
  • Drug Transport and Resistance Mechanisms
  • Drug-Induced Hepatotoxicity and Protection
  • Blood disorders and treatments
  • Pharmaceutical studies and practices
  • Immunodeficiency and Autoimmune Disorders

University of South Alabama
2003-2024

University of Nevada, Reno
2004-2009

University of Nevada, Las Vegas
2004-2007

Cincinnati Children's Hospital Medical Center
1989-1992

Boston Children's Hospital
1990

University of Cincinnati
1989

Hospital Research Foundation
1989

This is the first clinical practice guideline from American Academy of Pediatrics that specifically applies to patients who have experienced an apparent life-threatening event (ALTE). has 3 objectives. First, it recommends replacement term ALTE with a new term, brief resolved unexplained (BRUE). Second, provides approach patient evaluation based on risk infant will repeat or serious underlying disorder. Finally, management recommendations, key action statements, for lower-risk infants. The...

10.1542/peds.2016-0590 article EN PEDIATRICS 2016-04-25

Polyethylene glycol (PEG) 3350 and lactulose were compared in an unblinded, randomized, crossover design for treatment of constipation 37 children aged 2 to 16 years. Subjects received (1.3 g/kg/d divided twice daily up 20 g) or PEG (10 g/m /day) weeks. significantly decreased the total colonic transit time (47.6 +2.7 vs 55.3 ±2.4 hours, mean ±SE, lactulose, respectively, p = 0.038). The stool frequency, form, ease passage similar each laxative. is effective laxative chronic children.

10.1177/000992280204100405 article EN Clinical Pediatrics 2002-05-01

Two gastroesophageal reflux disease (GERD) symptom questionnaires were developed and tested prospectively in a pilot study conducted infants (1 through 11 months) young children 4 years) with without clinical diagnosis of GERD. A pediatric gastroenterologist made the Parents or guardians at sites completed questionnaires, providing information on frequency severity symptoms appropriate to 2 age cohorts. In infants, assessed back arching, choking gagging, hiccups, irritability, refusal feed...

10.1097/01.mpg.0000172885.77795.0f article EN Journal of Pediatric Gastroenterology and Nutrition 2005-07-28

This clinical practice guideline has 2 primary objectives. First, it recommends the replacement of term "apparent life-threatening event" (ALTE) with a new term, "brief resolved unexplained (BRUE). Second, provides an approach to evaluation and management that is based on risk infant will have repeat event or serious underlying disorder.Clinicians should use BRUE describe occurring in younger than 1 year when observer reports sudden, brief, now episode ≥1 following: (1) cyanosis pallor; (2)...

10.1542/peds.2016-0591 article EN PEDIATRICS 2016-04-25

In 2016, the American Academy of Pediatrics published a clinical practice guideline that more specifically defined apparent life-threatening events as brief resolved unexplained (BRUEs) and provided evidence-based recommendations for evaluation infants who meet lower-risk criteria subsequent event or serious underlying disorder. The did not provide meeting higher-risk criteria, an important common population patients. Therefore, we propose tiered approach management have experienced BRUE....

10.1542/peds.2018-4101 article EN PEDIATRICS 2019-07-26

10.1016/s0002-9629(25)00219-8 article EN cc-by-nc-nd The American Journal of the Medical Sciences 2025-01-15

Thirty-four patients, aged 3 to 17 years, were randomized receive oral sodium phosphate solution or a polyethylene glycol-based in preparation for elective colonoscopy. Nineteen patients received two doses of (45 mL/1.7 m2/ dose) and 15 (4 L/1.7 m2). Compliance with was judged as easy tolerable 19 but only 5 who given solution. The quality colon cleansing rated by an endoscopist blinded the method used. bowel excellent good (only liquid remaining colonic lumen) 18 6 incidence vomiting...

10.1097/00005176-199612000-00013 article EN Journal of Pediatric Gastroenterology and Nutrition 1996-12-01

ABSTRACT Objective: To evaluate symptom improvement in 53 children (aged 5‐11 years) with endoscopically proven gastroesophageal reflux disease (GERD) treated pantoprazole (10, 20 and 40 mg) using the GERD Assessment of Symptoms Pediatrics Questionnaire. Methods: The Questionnaire was used to measure frequency severity over previous 7 days abdominal/belly pain, chest pain/heartburn, difficulty swallowing, nausea, vomiting/regurgitation, burping/belching, choking when eating pain after...

10.1097/01.mpg.0000214160.37574.d3 article EN Journal of Pediatric Gastroenterology and Nutrition 2006-04-01

Lidocaine, an aminoethylamide, undergoes deethylation in the liver after intravenous injection, resulting formation of monoethylglycinexylidide. Serum monoethylglycinexylidide concentration can be measured by a simple, rapid fluorescent polarization immunoassay. We sought to determine whether lidocaine metabolism, as indicated formation, could used quantitative index hepatic function. Therefore we 10 healthy children and 28 with chronic disease. Patients disease were divided severity being...

10.1002/hep.1840120319 article EN Hepatology 1990-09-01

To assess the efficacy and safety of lansoprazole in treatment adolescents with symptomatic, endoscopically proven, non-erosive gastroesophageal reflux disease erosive esophagitis.Adolescents between 12 17 years age esophagitis were enrolled this open-label trial treated 15 mg (non-erosive) or 30 (erosive) once daily for 8 weeks. If unhealed at week 8, those an additional 4 weeks daily.Lansoprazole produced a significant reduction from baseline median percentage days symptoms (91 to 43% 64...

10.1097/01.mpg.0000155369.54464.41 article EN Journal of Pediatric Gastroenterology and Nutrition 2005-02-24

A gene encoding the mitochondrial dicarboxylate transport protein (DTP) has been identified for first time from any organism. Our strategy involved overexpression of putative transporter genes, selected based on analysis yeast genome, followed by purification and functional reconstitution resulting products. The DTP Saccharomyces cerevisiae encodes a 298-residue basic which, in common with other anion transporters known sequence function, displays signature motif, three homologous 100-amino...

10.1074/jbc.272.7.4516 article EN cc-by Journal of Biological Chemistry 1997-02-01

Utilizing site-directed mutagenesis in combination with chemical modification of mutated residues, we have studied the roles cysteine and arginine residues mitochondrial citrate transport protein (CTP) from <i>Saccharomyces cerevisiae</i>. Our strategy consisted sequential replacement each four endogenous Ser or case Cys<sup>73</sup> Val. Wild-type forms CTP were overexpressed <i>Escherichia coli</i>, purified, reconstituted phospholipid vesicles. During Cys, effects both hydrophilic...

10.1074/jbc.275.10.7117 article EN cc-by Journal of Biological Chemistry 2000-03-01

Summary: The American Academy of Pediatrics recommends oral rehydration and early refeeding for management infants with diarrhea mild to moderate dehydration. However, intravenous is still widely used treatment hospitalized administration solution via continuous infusion through a nasogastric tube facilitates its delivery in children. purpose this study compare children Infants who failed attempts at were dehydration due acute diarrheal illness randomized receive or rehydration. Following...

10.1097/00005176-199508000-00004 article EN Journal of Pediatric Gastroenterology and Nutrition 1995-08-01

The causal relationship between lactose ingestion and gastrointestinal symptoms is questionable. aim of this study was to assess associated with milk in children maldigestion. Thirty (11 males) age 3 17 years maldigestion were studied. In a double-blind, crossover design, subjects ingested 240 m L daily either lactose-hydrolyzed or lactose-containing for 14 days. Diaries kept that recorded diet, medication use, symptoms. There significant increase abdominal pain experienced by participants...

10.1177/000992280304200406 article EN Clinical Pediatrics 2003-05-01

Objectives: To evaluate the pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability of lansoprazole in adolescents between 12 17 years age with gastroesophageal reflux disease (GERD). Methods: Adolescents symptomatic, endoscopically and/or histologically proven GERD were enrolled this multicenter, double-blind trial randomized to 15 mg or 30 once daily for 5 days. Results: Sixty-three study. After administration, Tmax occurred at 1.6 hours those treated 1.7 mg....

10.1097/00005176-200211004-00005 article EN Journal of Pediatric Gastroenterology and Nutrition 2002-11-01

Objectives: To evaluate the pharmacokinetics and pharmacodynamics of lansoprazole in children between 1 11 years age with gastroesophageal reflux disease (GERD). Methods: In a multicenter, open-label trial pediatric patients symptomatic GERD, were assigned, based on their weight, to receive 15 mg (patients weighing ≤30 kg) or 30 > once daily. The effects 24-hour median intragastric pH, percentages time pH was above 3 4, pharmacokinetic parameters assessed at day-5 visit compared baseline....

10.1097/00005176-200211004-00004 article EN Journal of Pediatric Gastroenterology and Nutrition 2002-11-01
Coming Soon ...